Phase 1 study with topical cream RLS-1496 in patients with plaque psoriasis
Latest Information Update: 15 Jul 2026
At a glance
- Drugs RLS-1496 (Primary)
- Indications Atopic dermatitis; Plaque psoriasis; Skin aging
- Focus Adverse reactions; First in man
- Sponsors Rubedo Life Sciences
Most Recent Events
- 11 Mar 2026 Status changed from recruiting to completed.
- 17 Sep 2025 According to a Rubedo Life Sciences media release, results from this trial are expected in Q4 2025.
- 22 May 2025 According to a Rubedo Life Sciences media release, design of the trial was developed with key insights provided by Rubedo's Clinical Advisory Board (CAB) and trial is led by Rubedo Chief Medical Officer and dermatologist Mary Spellman, MD.